CD8A and neoplasm: While it is impossible to discern definitively the benefit of the immunotherapy in NAC-ICI, this manuscript provides evidence that immunotherapy could have effects (e.g. decreased % PD-1 + CD8 T cells), and these effects are consistent with improved tumor response.